Haleon PLC Sponsored ADR (HLN)
(Delayed Data from NYSE)
$8.38 USD
-0.08 (-0.95%)
Updated May 24, 2024 04:00 PM ET
After-Market: $8.39 +0.01 (0.12%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HLN 8.38 -0.08(-0.95%)
Will HLN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HLN
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
HLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
HLN vs. ABT: Which Stock Is the Better Value Option?
Other News for HLN
Warning: HLN is at high risk of cutting its dividend
Haleon Executives Invest in Company’s Future
GSK plc Divests Entire Stake in Haleon PLC
Haleon CFO Acquires Shares via Dividend
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale